We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Learn about drug types, stages, administration routes, and molecular classifications. Explore therapies under development, emerging drugs, and key pl ...

COPD cases are rising in women. Uncover the latest insights to enhance diagnosis and treatment in your women patients.

Sage vs QuickBooks 2025: Which Software Is Best? Your email has been sent Trying to choose between QuickBooks and Sage? We’re here to break down pricing, features, and pros and cons to make your ...

Detailed price information for Sage Therapeutic Com (SAGE-Q) from The Globe and Mail including charting and trades.

Detailed price information for Sage Therapeutic Com (SAGE-Q) from The Globe and Mail including charting and trades.

In the mergers and acquisitions space, Biogen failed a $469m takeover bid of Sage Therapeutics in January. Give your business an edge with our leading industry insights. Give your business an edge ...

SAGE markets its new depression drug Zurzuvae (zuranolone) in partnership with drug giant Biogen BIIB. Zurzuvae, the first and only oral treatment indicated for adults with postpartum depression ...

Sage Therapeutics, Inc. SAGE reported a loss of $1.01 per share for the first quarter of 2025, wider than the Zacks Consensus Estimate of a loss of 99 cents. The company had reported a loss of $1. ...

(Find the latest EPS estimates and surprises on Zacks Earnings Calendar.) SAGE markets its new depression drug Zurzuvae (zuranolone) in partnership with drug giant Biogen BIIB. Zurzuvae, the first and ...